Company intelligence / Profile preview

Xcision Medical Systems

Columbia, Maryland, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

GammaPod received FDA 510(k) clearance in January 2018 and CE Mark approval in April 2019. The system enables partial breast radiation treatment in 5 days or less compared to conventional therapy lasting 4-6 weeks. Clinical research through the GammaPod Research Consortium is evaluating treatment shortening and ablative dose delivery protocols. Researchers have confirmed geometric and dosimetric accuracy, identified patient suitability criteria, and documented patient comfort.

Therapeutic areas: Oncology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

University of Maryland School of MedicineGammaPod Research Consortium

Beyond the preview

Go deeper on Xcision Medical Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xcision Medical Systems.

Explore the full profile